Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Ideaya Biosciences, Broad Institute Partner on Synthetic Lethality-Based Cancer Drug Discovery

Ideaya Biosciences, Broad Institute Partner on Synthetic Lethality-Based Cancer Drug Discovery

Oct 22, 2020
|
staff reporter

NEW YORK – Ideaya Biosciences on Thursday announced that it had partnered with the Sellers Laboratory at the Broad Institute of MIT and Harvard to generate target and biomarker discoveries for the treatment of patients with ovarian and breast cancers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Dec
15
Featured Webinar

Case Study: Deployment of High-Throughput SARS-CoV-2 Testing at UC Davis

Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.

What's Popular?

In Cancer

  1. Illumina, New York Healthcare Providers, NYGC Partner on Clinical Whole-Genome Sequencing

  2. Illumina, PierianDx Expand Partnership on Cancer Panel Test Reporting

  3. Epigenome Study Maps Hydroxymethylation Across Diverse Human Tissue Types

  4. Grail Inks Deal With UK National Health Service to Offer Cancer Screening Blood Test in 2021

  5. Diaceutics, Alva10 Gathering Evidence Base for Improving PD-L1 Test Reimbursement

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.